Savient Pharmaceuticals to Present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference

Savient Pharmaceuticals Inc. (NASDAQ: SVNTE), an
emerging specialty pharmaceuticals company focused on developing,
manufacturing and marketing novel therapeutic products for unmet
medical needs, today announced that Christopher Clement, President and
Chief Executive Officer, will present at the Rodman & Renshaw Techvest
Healthcare Conference on Wednesday, November 9, 2005 at 11:15 a.m. EST
at the New York Palace Hotel.

   A live webcast of the presentation can be accessed under the News
section of Savient's website at www.savientpharma.com and will be
archived through November 23, 2005. Please connect to the website
several minutes prior to the start of the presentation to ensure
adequate time for any software download that may be required.

   About Savient Pharmaceuticals, Inc.

   Based in East Brunswick, New Jersey, Savient Pharmaceuticals, Inc.
is a specialty pharmaceutical company dedicated to developing,
manufacturing and marketing novel therapeutic products that address
unmet medical needs. The Company's lead product development candidate,
Puricase(R), for the treatment of refractory gout has reported
positive Phase 1 and 2 clinical data. Savient's experienced management
team is committed to advancing its pipeline and expanding its product
portfolio by in-licensing late stage compounds and exploring
co-promotion and co-development opportunities that fit the Company's
expertise in specialty pharmaceuticals and initial focus in
rheumatology. The Company's operations also include a wholly-owned
U.K. subsidiary, Rosemont Pharmaceuticals Ltd., which develops,
manufactures and markets liquid formulations of prescription
pharmaceutical products. Rosemont's product portfolio includes over 90
liquid formulations primarily targeting the geriatric population.
Further information on the Company can be accessed by visiting
www.savientpharma.com.